FCMI
EPZM

Foresite Capital Management II’s Epizyme, Inc EPZM Stock Holding History

Foresite Capital Management II’s Portfolio EPZM Stock Details EPZM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-150,000
Closed -$1.93M – 27
2015
Q3 		$1.93M Buy
+150,000
New +$3.03M 0.59% 21

Other funds holding EPZM

RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Foresite Capital Management II's EPZM Position: Q1 2022 in Review

Foresite Capital Management II sold out of Epizyme, Inc (EPZM) in Q1 2022, closing a stake of 690,002 shares — an estimated $1.73M sold.

Foresite Capital Management II first reported a position in EPZM in Q4 2014 and held it in 29 quarters. The position peaked at $29.4M in Q3 2017. 120 funds tracked by Wall St. Rank hold EPZM as of Q1 2022.

  • Foresite Capital Management II reported no remaining Epizyme, Inc position as of Q1 2022 after selling out during the quarter.
  • Foresite Capital Management II sold 690,002 Epizyme, Inc shares in Q1 2022, an estimated $1.73M.
  • Foresite Capital Management II first reported a position in Epizyme, Inc in Q4 2014 and held it in 29 quarters.
  • Foresite Capital Management II's Epizyme, Inc position peaked at $29.4M in Q3 2017.
  • 120 funds tracked by Wall St. Rank held Epizyme, Inc as of Q1 2022.

Based on Foresite Capital Management II's 13F filing for Q1 2022, filed 13 May 2022.